ArticleFrontiers in oncology2025
Integrating TBSRTC subcategorization and
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interpretable SVM-Based Integrated Ultrasound Model for Preoperative Thyroid Nodule Subtype Classification: Improved Identification of Follicular Variant Papillary Thyroid Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Integration of BRAF V600E mutation with contrast-enhanced ultrasound parameters provides complementary diagnostic value for malignant thyroid nodules.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the malignant risk of ultrasound-guided fine-needle aspiration (UG-FNA) cytology-diagnosed Bethesda III thyroid nodules and the significance of combined Methods: A retrospective analysis was conducted on UG-FNA results from 10,839 patients (12,528 nodules) at Deyang People's Hospital between December 2021 and September 2024. Liquid-based cytology (LBC) combined with cell block technology identified 732 Bethesda III nodules (detection rate: 5.8%). Among these, 180 cases with postoperative histological follow-up were analyzed, including 101 cases with preoperative Results: Among 180 Bethesda III nodules, malignancies accounted for 62.2% (112/180), predominantly papillary thyroid carcinoma (PTC; 110/112, 98.2%), while low-risk neoplasms and benign lesions constituted 15.0% (27/180) and 22.8% (41/180), respectively. Multivariate analysis identified nodule size <1 cm (P < 0.001) and the "nuclear atypia" subcategory as independent predictors, with the latter showing extreme predictive value for malignancy (OR = 121.854, P < 0.001; capturing 98.2% malignancies) and modest association with low-risk neoplasms (OR = 7.014, P = 0.001). Conclusion: In Bethesda III nodules, a diameter <1 cm or the "with nuclear atypia" subcategory indicates a high malignant risk (OR = 121.854), warranting active management. Preoperative
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.